Future Studies to Improve Cryocompression Application in Gynecologic Cancer

Video

Future research assessing cryocompression for those with gynecologic cancers will make use of different products to make the intervention easier and more accessible for patients.

At The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, Mary Katherine Montes de Oca, MD, spoke about plans to further investigate the use of cryocompression to reduce chemotherapy-induced peripheral neuropathy in patients with gynecologic cancers.

According to Montes de Oca, an Obstetrics and Gynecology resident at Duke University Medical Center, a limitation of the self-controlled trial involved application of cryocompression to 1 side of a patient’s body; a future randomized trial may change this by having patients receive the intervention on the entirety of their body. Additionally, she described the possibility of using other methods to allow patients to slide on shoes, gloves, or socks more easily for cryocompression, making the strategy more accessible.

Transcript:

We have a few ideas for a future study. I did a self-controlled design, which means the patient received ice and compression on one side and then had no intervention on the opposite side. If it works, then that means that patients have neuropathy on 1 side of their body. So, plans for future studies would be conventional randomization so that patients can receive the intervention on all of their limbs.

[We] also want to look into some better methods of applying the cryocompression. We used a compression sock, a tight surgical glove, and then bags of ice on the hands and feet. But there are some products that are made by different companies that are just a better method for sliding on the gloves, shoes, or socks, and are a little easier to use and also can be accessible to all of our patients.

Reference

Montes de Oca MK, Unnithan S, Erkanli AE, et al. Use of cryocompression to reduce peripheral neuropathy in gynecologic cancer: a randomized controlled trial. Presented at: 2023 SGO Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, Florida.

Recent Videos
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.
Related Content